MedDataX Logo

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

NCT ID: NCT00505830

Last Updated: 2007-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.

The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.

Secondary objectives are to:

Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.

Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.

Define the threshold of positivity for the 3 questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ \>85.

Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70\<IQ\<84.

Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France).

Multicentre study: 8 clinical centres and 18 paediatricians

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asperger Syndrome Autism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ \>85.

questionnaires

Intervention Type OTHER

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

2

50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70\<IQ\<84.

questionnaires

Intervention Type OTHER

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

3

50 adolescents with psychiatric disorders but no autism syndrom.

questionnaires

Intervention Type OTHER

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

4

Sample of 50 healthy adolescents selected randomly from 200.

questionnaires

Intervention Type OTHER

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 1 (AS/HFA) and 2 (AS/classic autism) :

* Boys and girls aged 12 to 18
* Patients with autism or Asperger syndrome according to the diagnostic criteria (ICD 10)
* Patients receiving education in an ordinary school
* IQ\>70

Group 3 (adolescents with psychiatric disorders):

* Boys and girls aged 12 to 18
* Patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome
* Patients receiving education in an ordinary school when not in hospital

Group 4 (adolescent without psychiatric syndrome):

* Boys and girls aged 12 to 18
* Patients receiving education in an ordinary school

Exclusion Criteria

For all groups :

* Problem with language or comprehension
* Participants who have not given their consent
Minimum Eligible Age

12 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Joint Clinical Research Center

OTHER

Sponsor Role collaborator

Groupe Francais d'Epidemiologie Psychiatrique

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sabine Manificat, MDH

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Saint Jean de Dieu

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Saint Jean de Dieu

Lyon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean-Pierre Vignat, MDH

Role: CONTACT

[email protected]
+33 4 37 90 11 75

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sabine Manificat, MDH

Role: primary

[email protected]
+33 4 37 90 12 96

Berhouz Kassai, MD, PhD

Role: backup

[email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Autisme AQ

Identifier Type: -

Identifier Source: org_study_id